Patient Preference for Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam or Topical Suspension vs. Latest Topical Treatment in the PSO-INSIGHTFUL Study. (2017). SKIN The Journal of Cutaneous Medicine, 1(3.1), s26. https://doi.org/10.25251/skin.1.supp.25